Healthcare -
Biotechnology - NASDAQ - US
$ 64.68
-1.61 %
$ 4.63 B
Market Cap
-16.46
P/E
1. INTRINSIC VALUE
Balance Sheet
Nuvalent, Inc.
| Current Assets | 1.13 B |
| Cash & Short-Term Investments | 1.12 B |
| Receivables | 0 |
| Other Current Assets | 14.1 M |
| Non-Current Assets | 9.3 M |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 9.3 M |
| Current Liabilities | 54 M |
| Accounts Payable | 5.22 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 48.8 M |
| Non-Current Liabilities | 17.9 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 17.9 M |
EFFICIENCY
Earnings Waterfall
Nuvalent, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 280 M |
| Operating Income | -280 M |
| Other Expenses | -19.6 M |
| Net Income | -261 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuvalent, Inc.
| Net Income | -261 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 60.6 M |
| Change in Working Capital | 11.8 M |
| Others | 19.2 M |
| Free Cash Flow | -185 M |
Wall Street Analysts Price Targets
Nuvalent, Inc.
Wall Street analysts predict an average 1-year price target for NUVL of $115 , with forecasts ranging from
a
low of
$100 to a high of $135 .
NUVL Lowest Price Target
Wall Street Target
100 USD
54.61%
NUVL Average Price Target
Wall Street Target
115 USD
77.54%
NUVL Highest Price Target
Wall Street Target
135 USD
108.72%
4. DIVIDEND
ANALYSIS
NUVL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Nuvalent, Inc.
Sold
0-3 MONTHS
7.23 M USD 3
3-6 MONTHS
220 M USD 9
6-9 MONTHS
13.9 M USD 7
9-12 MONTHS
17 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
CAMBRIDGE, Mass. , April 1, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
prnewswire.com
- 2 weeks ago
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
CAMBRIDGE, Mass. , March 25, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced upcoming poster presentations further characterizing the preclinical profiles of its novel ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib, at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25-30, 2025, in Chicago.
prnewswire.com
- 3 weeks ago
Nuvalent to Participate in Upcoming March Investor Conferences
CAMBRIDGE, Mass. , Feb. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
prnewswire.com
- 1 month ago
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results
Topline pivotal data expected in 2025 for both TKI pre-treated ROS1-positive and TKI pre-treated ALK-positive NSCLC populations First NDA submission planned for mid-year 2025 towards potential first approval in 2026 for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population Development strategies in place for TKI-naïve populations, including planned initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC in first half of 2025 Implemented global Expanded Access Programs for zidesamtinib and neladalkib, in line with goal of prioritizing patient access CAMBRIDGE, Mass. , Feb. 27, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and business progress, reiterated key anticipated milestones, and reported fourth quarter and full year 2024 financial results.
prnewswire.com
- 1 month ago
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data anticipated in the first half of 2025 Topline pivotal data for neladalkib (NVL-655) in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 th at 9:00 a.m.
prnewswire.com
- 3 months ago
Nuvalent: A Logical Acquisition Target
Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results and FDA designations. Nuvalent's robust financial position and pipeline make it a prime M&A target, with potential suitors like Pfizer, AstraZeneca, and Novartis. Downside risks include regulatory setbacks, commercialization challenges, strong competition, and financial management, but Nuvalent's cash runway is healthy until 2028.
seekingalpha.com
- 3 months ago
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
prnewswire.com
- 4 months ago
Nuvalent Appoints Grant Bogle to Board of Directors
CAMBRIDGE, Mass. , Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors.
prnewswire.com
- 4 months ago
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass , Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m.
prnewswire.com
- 4 months ago
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026 Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory Board Strong cash position of $1.2 billion, including proceeds from upsized $575 million public offering, expected to extend operating runway into 2028 CAMBRIDGE, Mass.
prnewswire.com
- 5 months ago
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3.
seekingalpha.com
- 6 months ago
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $100.00 per share.
prnewswire.com
- 7 months ago
8. Profile
Summary
Nuvalent, Inc. NUVL
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.63 B
Dividend Yield
0.00%
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Contact
One Broadway, Cambridge, MA, 02142
https://www.nuvalent.com
IPO
Date
July 29, 2021
Employees
142
Officers
Dr. Benjamin Lane Ph.D.
Senior Vice President of Technical Operations
Dr. Henry Pelish Ph.D.
Chief Scientific Officer
Dr. James R. Porter Ph.D.
Chief Executive Officer, President & Director
Ms. Deborah Ann Miller J.D., Ph.D.
Chief Legal Officer & Secretary
Mr. Matthew Metivier M.B.A.
Senior Vice President of Human Resources
Ms. Darlene Noci
Chief Development Officer
Ms. Alexandra Balcom CPA, M.B.A.
Chief Financial Officer & Treasurer
Mr. John Soglia Ph.D.
Senior Vice President of Translational Development
Prof. Matthew D. Shair Ph.D.
Founder, Head of Scientific Advisory Board & Director
Dr. Christopher D. Turner M.D.
Chief Medical Officer